Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in Children
Status:
Not yet recruiting
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that anakinra provides more rapid disease control
than steroids in the first month of treatment in the event of recurrent pericarditis and is
more effective in preventing further exacerbations in patients aged between eight months and
eighteen years of age with idiopathic or post-procedural pericarditis, unresponsive to
first-line treatment with NSAIDs and colchicine at the appropriate dosage, or in case of
colchicine intolerance. The efficacy of the two treatments will be evaluated by the capacity
and timing of the two therapies to determine a complete control (clinical, laboratory and
instrumental) of the disease and the absence of recurrences.
Phase:
Phase 3
Details
Lead Sponsor:
Istituto Giannina Gaslini
Treatments:
Interleukin 1 Receptor Antagonist Protein Prednisone